Pharmbio's Orafang was published in the JCC

Comparative clinical trials with 2L PEGs for IBD patients

Pharmbio (Chairman Nam Bong-gil) announced on the 12th that the comparative clinical results on the use of Orafang PO and 2L PEG drugs for IBD patients in Ccaid were introduced in the famous journal Journal of Cron's and Colitis.

 

JCC is an SCIE-class medical journal in the field of inflammatory bowel disease published by Oxford University Press (OUP), and is a prestigious paper with an impact index of 9.485 over the past five years.

 

In the paper, the comparative clinical results of the intestinal crystallinity (HCS) of the two preparations revealed that the intestinal tract of Orafang was significantly excellent in all compartments such as ascending colon (3.06<3.38), transverse colon (3.25<3.62), descending colon (3.17<3.69), S-phase colon (3.06<3.38) and rectum (3.17<3.69) as a result of comparative clinical trials of the two drugs.

 

In addition, as a result of the efficacy evaluation, the proportion of patients without bubbles was 94.5% of Orafang and 50% of 2L PEG, which was significantly higher in the Orafang group, and in particular, the willingness to take it (94.5%) was significantly higher than that of 2L PEG (78%).

 

In conclusion, Orafang showed a high level of intestinal cleansing comparable to 2L PEG in IBD patients, while patient satisfaction was much higher.

 

Pharmbio expects the use of Orafang to be added as a recommendation for colonoscopy laxative prescription to IBD patients through this paper in the future.

 

Chairman Nam Bong-gil of Pharmbio said, "We are happy to have proven Orafang's effectiveness, and safety internationally through this international journal." "We will continue to do our best to develop excellent new drugs that are safe and have high patient satisfaction," he said.